MX2019009292A - Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. - Google Patents

Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.

Info

Publication number
MX2019009292A
MX2019009292A MX2019009292A MX2019009292A MX2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A MX 2019009292 A MX2019009292 A MX 2019009292A
Authority
MX
Mexico
Prior art keywords
methods
prader
willi syndrome
amino
carboxylic acid
Prior art date
Application number
MX2019009292A
Other languages
English (en)
Inventor
During Matthew
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2019009292A publication Critical patent/MX2019009292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan métodos de tratamiento de un trastorno convulsivo con ácido (1S,3S)-3-amino-4-(difluorometiliden)ciclopentan-1-carbo xílico o ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-en-1-c arboxílico (KT-II-115) o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Los métodos proporcionan composiciones terapéuticas que pueden utilizarse para mejorar uno o más de los síntomas de un trastorno convulsivo. Se proporcionan métodos de tratamiento del síndrome de Prader-Willi con ácido (1S,3S)-3-amino-4-(difluorometiliden)ciclopentan-1-carboxílico o acido (S)-3-amino-4-(difluorometilenil)ciclopent-1-en-1-carboxílic o (KT-II-115) o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Los métodos proporcionan composiciones terapéuticas que pueden utilizarse para mejorar uno o más de los síntomas del síndrome de Prader-Willi.
MX2019009292A 2017-02-08 2018-02-08 Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. MX2019009292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456320P 2017-02-08 2017-02-08
PCT/US2018/017382 WO2018148380A1 (en) 2017-02-08 2018-02-08 Methods of treating seizure disorders and prader-willi syndrome

Publications (1)

Publication Number Publication Date
MX2019009292A true MX2019009292A (es) 2019-09-13

Family

ID=63038393

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009292A MX2019009292A (es) 2017-02-08 2018-02-08 Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi.
MX2023009631A MX2023009631A (es) 2017-02-08 2019-08-05 Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023009631A MX2023009631A (es) 2017-02-08 2019-08-05 Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.

Country Status (10)

Country Link
US (4) US20180221319A1 (es)
EP (1) EP3579826A4 (es)
JP (2) JP2020506240A (es)
KR (1) KR20190111105A (es)
CN (1) CN110461319A (es)
AU (1) AU2018219861B2 (es)
CA (1) CA3051699A1 (es)
IL (2) IL268212B2 (es)
MX (2) MX2019009292A (es)
WO (1) WO2018148380A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
AU2019216742B2 (en) 2018-02-08 2024-05-09 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
WO2019191525A1 (en) * 2018-03-29 2019-10-03 Ovid Therapeutics Inc. Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
MX2020013290A (es) 2018-06-07 2021-04-29 Ovid Therapeutics Inc Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico y compuestos relacionados, acido (1s,3s)-3-amino-4-(difluorometilideno) ciclopentano-1-carboxilico y vigabatrina en el tratamiento de trastornos del desarrollo.
CN113496359B (zh) * 2021-07-13 2022-03-22 天津大学 一种多组合主客观均匀优化赋权风险评价方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) * 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
IL177609A (en) 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma
WO2009023601A2 (en) * 2007-08-11 2009-02-19 Argenis Llc Apparatus and methods for treating epilepsy using convection-enhanced delivery
EP2542234A4 (en) * 2010-02-25 2013-07-31 Univ Northwestern METHODS OF USING (1S, 3S) -3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID
US20140315992A1 (en) * 2011-07-07 2014-10-23 The Children's Hospital Of Philadelphia Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
KR20180052782A (ko) 2015-10-09 2018-05-18 노오쓰웨스턴 유니버시티 간질, 중독 및 간세포암종의 치료를 위한 gaba 아미노트랜스페라제 불활성화제들로서 (s)-3-아미노-4-(디플루오로메틸레닐)사이클로펜트-1-엔-1-카르복실산, 및 관련된 화합물들, 및 관련된 화합물들

Also Published As

Publication number Publication date
US20200000757A1 (en) 2020-01-02
EP3579826A1 (en) 2019-12-18
IL268212B2 (en) 2024-06-01
US20240173280A1 (en) 2024-05-30
MX2023009631A (es) 2023-08-28
WO2018148380A1 (en) 2018-08-16
JP2020506240A (ja) 2020-02-27
CN110461319A (zh) 2019-11-15
JP2023025040A (ja) 2023-02-21
US20180221319A1 (en) 2018-08-09
CA3051699A1 (en) 2018-08-16
AU2018219861B2 (en) 2022-03-31
IL268212B1 (en) 2024-02-01
KR20190111105A (ko) 2019-10-01
EP3579826A4 (en) 2020-11-18
US20230149332A1 (en) 2023-05-18
US11918551B2 (en) 2024-03-05
IL268212A (en) 2019-09-26
IL310065A (en) 2024-03-01
AU2018219861A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
MX2023009631A (es) Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi.
MX2021009673A (es) Moduladores de ror-gamma.
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2018010788A (es) Composicion oftalmologica.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
WO2016161055A3 (en) Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
JOP20200134A1 (ar) تركيبات وطرق لمعالجة حالات أيضية
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019004321A (es) Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
AU2016298962A8 (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.